-

Eurofins Medical Device Services Launches first GMP PFAS Screening and Testing Solutions for Medical Devices

LANCASTER, Pa.--(BUSINESS WIRE)--Eurofins Medical Device Services North America, part of a global network of over 20 medical device testing laboratories and a leading medical device solutions partner, recently launched a GMP PFAS testing and screening solution, the first developed and commercialized for the medical device industry. This offering provides insights to medical device manufacturers as they navigate the complex and evolving global regulations surrounding PFAS, ultimately contributing to medical device and patient safety.

Per- and polyfluoroalkyl substances, or PFAS, are a group of more than twenty thousand chemical compounds which are highly resistant to degradation and have been found to pose potential threats to human health and the environment. Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates and avoid future shutdowns, recalls, and liability issues, while further supporting their sustainability goals.

Eurofins Medical Device Services North America’s GMP PFAS testing and screening solution includes:

  • Combustion Ion Chromatography (CIC) for total organic fluorine screening in solids, liquids, and gases, to provide an initial assessment of PFAS levels.
  • Process mapping and supply chain audits, to identify contamination pathways.
  • Solvent extraction and direct combustion for flexible sample formats.
  • Extractables & Leachables (E&L) testing, toxicological risk assessments, and aging studies.
  • Stability and forced degradation studies, to identify PFAS breakdown products.

Eurofins Medical Device Services North America operates under ISO 17025 accreditation standards, and applies GMP best practices, ensuring sensitivity, specificity, and reproducibility even at trace levels.

Learn more at https://www.eurofins.com/medical-device/

About Eurofins Medical Device Services

Eurofins Medical Device Services offers comprehensive testing, consulting, and regulatory support for Class I, II, and III medical devices—including implants, instruments, single-use and combination products, and wearables.

With more than 40 years of experience, our global network of medical device testing laboratories and consultants provide strategic guidance from biological evaluation plans through commercialization, and specialize in international regulatory requirements, scientific trends, and tailored testing strategies.

Committed to global standards, Eurofins Medical Device Services designs and executes testing plans aligned with ISO, ASTM, ANSI, and AAMI standards, as well as custom methodologies. Our quality systems meet GMP and ISO 17025 requirements, helping clients accelerate market access with confidence.

Contacts

For further information:
Lisa Bamford
Medical Device Services Communications Director
Lisa.bamford@bpt.eurofinsus.com

Eurofins

BOURSE:ERF

Release Versions

Contacts

For further information:
Lisa Bamford
Medical Device Services Communications Director
Lisa.bamford@bpt.eurofinsus.com

More News From Eurofins

Eurofins Scientific SE: Weekly Report on Share Repurchases From 09th March to 13th March 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 09/03/2026 FR0014000MR3 10 000 63.1848 CEUX EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 09/03/2026 FR0014000MR3 30 000 63.1292 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 10/0...

Eurofins Biomnis Launches New Clinical LC‑MS/MS Method for the Detection of Cereulide Toxin in Stool Samples

LYON, France--(BUSINESS WIRE)--Eurofins Biomnis, a leading European provider of specialised clinical diagnostics services, and part of the global network of Eurofins laboratories, announces the successful development and validation of a new liquid chromatography tandem mass spectrometry (LC‑MS/MS) method for the detection and quantification of cereulide toxin in human stool samples. This innovation underlines Eurofins Biomnis’ diagnostic innovation, and its commitment to contributing its expert...

Eurofins Scientific SE: Weekly Report on Share Repurchases from 02nd March to 06th March 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 02/03/2026 FR0014000MR3 30 000 67.7739 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 02/03/2026 FR0014000MR3 10 000 67.7248 CEUX EUROFINS SCIENTIFIC 529900JEHFM...
Back to Newsroom